Vogmask® Awarded CE Mark Approval for Reusable Organic Filtering Face Masks Respiratory Protective Device
Air quality is the biggest threat to public health today. One important tool for breathing clean air is a filtering face mask. First in market to bring fashion to high efficiency, Vogmask has been awarded CE Mark Certificates on expanded range of Organic General Use Respirators to address the environmental challenges of poor air quality.
Notified Body BSI has awarded CE Mark Certificates for the Vogmask®
Organic product line certifying compliance with international regulatory
Personal Protective Equipment (PPE) Directive 89/686/EEC and
General Product Safety Directive 2001/95 EC.
Vogmask Organics complements its premier CE Certified high fashion microfiber products. Organic cotton face-blanks provide cooler mask wearing in warm temperatures, natural material, and dual exhale valves in Certified Reusable masks.
Now offered in forty-one countries, worldwide, Vogmask is recognized as the premier face mask for fit, comfort, filtering efficiency, ecology, and style.
Vogmask® is a Registered Trademark of Ohlone Press, LLC.
Ohlone Press, LLC, received assistance from MPR Associates, Inc. in preparing technical and Quality Assurance content of the CE Mark application. MPR provides design, engineering, and regulatory compliance services for medical and consumer health care companies.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
FOCP19.11.2017 17:33 | pressemeddelelse
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life
ASTRAZENECA19.11.2017 00:02 | pressemeddelelse
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases
ASTRAZENECA18.11.2017 19:22 | pressemeddelelse
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer
CHINA-HI-TECH-FAIR18.11.2017 10:13 | pressemeddelelse
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled
NY-MADISON-REALTY17.11.2017 17:22 | pressemeddelelse
Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn
NCARDIA17.11.2017 13:33 | pressemeddelelse
Ncardia Announces Completion of €10.5M Investment Round
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum